Selective killing of cancer cells by small molecules targeting heat shock stress response

Daniel Zhang1, Bin Zhang1

  • 1Department of Biology, Alpine Therapeutics, Inc., 13350 Camino Del Sur, No. 8, San Diego, CA 92129, USA.

Insights

Researchers identified novel compounds targeting the heat shock factor 1 (HSF1) pathway for cancer therapy. These inhibitors show potent cancer cell growth inhibition with low normal cell toxicity, offering a promising new avenue for drug development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Heat shock response mediated by heat shock factor 1 (HSF1) is a potential non-oncogenetic target in cancer therapy.
  • Reporter-based high-throughput screening has identified HSF1 inhibitors, but limitations may cause biased results.

Purpose of the Study:

  • To identify novel HSF1 pathway inhibitors using a high-content image-based phenotypic screen.
  • To validate the mechanism of action and therapeutic potential of identified compounds.

Main Methods:

  • Phenotypic screening of over 100,000 compounds using a validated high-content image-based assay targeting the HSF1 pathway.
  • Western blot analysis to confirm HSF1 phosphorylation inhibition and HSP protein reduction.
  • Validation of HSF1-dependent mechanism using HSF1 shRNA in HeLa cells.

Main Results:

  • Identification of novel chemotypes functionally inhibiting the HSF1 pathway.
  • Selective compounds demonstrated nanomolar potency against multiple cancer cell lines.
  • Compounds exhibited low cytotoxicity to normal cells, with HSF1 knockdown conferring resistance.

Conclusions:

  • The study identified potent and selective HSF1 pathway inhibitors with potential as next-generation anticancer drugs.
  • The validated HSF1-dependent mechanism supports further development for targeted cancer therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.3K